En based on the analysis of some 3,000 patients admitted since mid-March, the researchers found that the average survival time of patients increased from 14 days to 21 days with the addition of anticoagulants, according to the Medscape website .
The effect was particularly marked in the sickest patients who needed artificial respiration aid: the death rate plunged from 62.7% to 29.1% with anticoagulant therapy. The average survival time decreased from nine days to 21 days.
An official at Mount Sinai said that all admitted SARS-CoV-2 patients will now receive anticoagulants, unless medically contraindicated.
COVID-19 seems to promote the formation of clots, but the exact role of anticoagulants in the fight against the disease remains to be clarified.
The study was published by the Journal of the American College of Cardiology.